Skip to search formSkip to main contentSkip to account menu

PD 0332991

Known as: PD-0332991, PD-332991, PD0332991 
An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

palbociclib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells
PD0332991 (palbociclib/Ibrance®) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the… 
2015
2015
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective… 
Highly Cited
2014
Highly Cited
2014
Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy
Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key… 
2014
2014
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
CDK4 and CDK6 bound to D-type cyclins are master integrators of G1 phase cell cycle regulations by initiating the inactivating… 
Review
2014
Review
2014
Endocrine therapy for advanced breast cancer.
The demonstrated efficacy of pharmacologic antiestrogen therapy in treating hormone receptor-positive breast cancer has changed… 
2013
2013
A Whole-Genome RNA Interference Screen for Human Cell Factors Affecting Myxoma Virus Replication
ABSTRACT Myxoma virus (MYXV) provides an important model for investigating host-pathogen interactions. Recent studies have also… 
2012
2012
The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated with Abnormal Activation of the Cyclin-CDK-Rb Pathway
Loss of normal growth control is a hallmark of cancer progression. Therefore, understanding the early mechanisms of normal growth… 
2012
2012
Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma.
8520 Background: Activation of CDK4 by amplification, increased expression of Cyclin D1 (CCND1) or reduced expression of the CDK… 
2010
2010
Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia
We read with great interest the work published by Dickstein et al. (1) showing that induced EVI1 expression in a murine model… 
2008
2008
Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11;14… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)